Global Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Research Report 2023

Publication ID:

PB503231871

Publication Date:

March 1, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

Rheumatoid arthritis stem cell therapy has been demonstrated to induce profound healing activity, halt arthritic conditions, and in many cases, reverse and regenerate joint tissue. Today, bone marrow transplant, adipose or fat-derived stem cells, and allogeneic mesenchymal stem cells (human umbilical cord tissue) are used for rheumatoid arthritis stem cell therapy. As the rheumatoid arthritis worsens, the body initiates autoimmune response and attacks the cells. Rheumatoid arthritis stem cell therapy is growing in popularity across hospitals, ambulatory surgical centers, and specialty clinics, as it increases the healing of joints and further treats the entire system that causes the joint pain and inflammation.
Highlights
The global Rheumatoid Arthritis Stem Cell Therapy market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Rheumatoid Arthritis Stem Cell Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Rheumatoid Arthritis Stem Cell Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Rheumatoid Arthritis Stem Cell Therapy in Hospitals is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Rheumatoid Arthritis Stem Cell Therapy include Mesoblast, Roslin Cells, Regeneus, ReNeuron Group, International Stem Cell Corporation and Takeda, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Rheumatoid Arthritis Stem Cell Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rheumatoid Arthritis Stem Cell Therapy.
The Rheumatoid Arthritis Stem Cell Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Rheumatoid Arthritis Stem Cell Therapy market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Rheumatoid Arthritis Stem Cell Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Mesoblast
Roslin Cells
Regeneus
ReNeuron Group
International Stem Cell Corporation
Takeda
Segment by Type
Allogeneic Mesenchymal Stem Cells
Bone Marrow Transplant
Adipose Tissue Stem Cells
Segment by Application
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Rheumatoid Arthritis Stem Cell Therapy companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Allogeneic Mesenchymal Stem Cells
1.2.3 Bone Marrow Transplant
1.2.4 Adipose Tissue Stem Cells
1.3 麻豆原创 by Application
1.3.1 Global Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Specialty Clinics
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Perspective (2018-2029)
2.2 Rheumatoid Arthritis Stem Cell Therapy Growth Trends by Region
2.2.1 Global Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Rheumatoid Arthritis Stem Cell Therapy Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Rheumatoid Arthritis Stem Cell Therapy Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Dynamics
2.3.1 Rheumatoid Arthritis Stem Cell Therapy Industry Trends
2.3.2 Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Drivers
2.3.3 Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Challenges
2.3.4 Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Rheumatoid Arthritis Stem Cell Therapy Players by Revenue
3.1.1 Global Top Rheumatoid Arthritis Stem Cell Therapy Players by Revenue (2018-2023)
3.1.2 Global Rheumatoid Arthritis Stem Cell Therapy Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Rheumatoid Arthritis Stem Cell Therapy Revenue
3.4 Global Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Concentration Ratio
3.4.1 Global Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Rheumatoid Arthritis Stem Cell Therapy Revenue in 2022
3.5 Rheumatoid Arthritis Stem Cell Therapy Key Players Head office and Area Served
3.6 Key Players Rheumatoid Arthritis Stem Cell Therapy Product Solution and Service
3.7 Date of Enter into Rheumatoid Arthritis Stem Cell Therapy 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Rheumatoid Arthritis Stem Cell Therapy Breakdown Data by Type
4.1 Global Rheumatoid Arthritis Stem Cell Therapy Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Rheumatoid Arthritis Stem Cell Therapy Forecasted 麻豆原创 Size by Type (2024-2029)
5 Rheumatoid Arthritis Stem Cell Therapy Breakdown Data by Application
5.1 Global Rheumatoid Arthritis Stem Cell Therapy Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Rheumatoid Arthritis Stem Cell Therapy Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Size (2018-2029)
6.2 North America Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Size by Country (2018-2023)
6.4 North America Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Size (2018-2029)
7.2 Europe Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Size by Country (2018-2023)
7.4 Europe Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Size (2018-2029)
9.2 Latin America Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Rheumatoid Arthritis Stem Cell Therapy 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Mesoblast
11.1.1 Mesoblast Company Detail
11.1.2 Mesoblast Business Overview
11.1.3 Mesoblast Rheumatoid Arthritis Stem Cell Therapy Introduction
11.1.4 Mesoblast Revenue in Rheumatoid Arthritis Stem Cell Therapy Business (2018-2023)
11.1.5 Mesoblast Recent Development
11.2 Roslin Cells
11.2.1 Roslin Cells Company Detail
11.2.2 Roslin Cells Business Overview
11.2.3 Roslin Cells Rheumatoid Arthritis Stem Cell Therapy Introduction
11.2.4 Roslin Cells Revenue in Rheumatoid Arthritis Stem Cell Therapy Business (2018-2023)
11.2.5 Roslin Cells Recent Development
11.3 Regeneus
11.3.1 Regeneus Company Detail
11.3.2 Regeneus Business Overview
11.3.3 Regeneus Rheumatoid Arthritis Stem Cell Therapy Introduction
11.3.4 Regeneus Revenue in Rheumatoid Arthritis Stem Cell Therapy Business (2018-2023)
11.3.5 Regeneus Recent Development
11.4 ReNeuron Group
11.4.1 ReNeuron Group Company Detail
11.4.2 ReNeuron Group Business Overview
11.4.3 ReNeuron Group Rheumatoid Arthritis Stem Cell Therapy Introduction
11.4.4 ReNeuron Group Revenue in Rheumatoid Arthritis Stem Cell Therapy Business (2018-2023)
11.4.5 ReNeuron Group Recent Development
11.5 International Stem Cell Corporation
11.5.1 International Stem Cell Corporation Company Detail
11.5.2 International Stem Cell Corporation Business Overview
11.5.3 International Stem Cell Corporation Rheumatoid Arthritis Stem Cell Therapy Introduction
11.5.4 International Stem Cell Corporation Revenue in Rheumatoid Arthritis Stem Cell Therapy Business (2018-2023)
11.5.5 International Stem Cell Corporation Recent Development
11.6 Takeda
11.6.1 Takeda Company Detail
11.6.2 Takeda Business Overview
11.6.3 Takeda Rheumatoid Arthritis Stem Cell Therapy Introduction
11.6.4 Takeda Revenue in Rheumatoid Arthritis Stem Cell Therapy Business (2018-2023)
11.6.5 Takeda Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Mesoblast
Roslin Cells
Regeneus
ReNeuron Group
International Stem Cell Corporation
Takeda

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.